Description
Indication & Scope
AnYouPing® Finotonlimab Injection is a combined platinum chemotherapy treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
- Mechanism: It is a recombinant humanized anti-PD-1 IgG4 monoclonal antibody, which blocks the binding of PD-1 and PD-L1 ligands, restores the anti-tumor immune response of endogenous T cells, and kills tumor cells.
- Drug class: Programmed death receptor 1 immune checkpoint inhibitor, injectable immunotherapy anti-tumor prescription medicine.
- Clinical use: Immunochemotherapy first-line treatment for unresectable recurrent and metastatic head and neck squamous cell carcinoma.
| Generic Name | Finotonlimab Injection |
| Brand Name | AnYouPing |
| Ingredient | Finotonlimab Injection |
| Dosage Form | Injection |
| Package | 100mg(4ml)*1 vial/box |
| Conditions Treated | Recurrent and/or metastatic head and neck squamous cell carcinoma |
| Taboos | Patients with severe hypersensitivity to finotonlimab or preparation excipients; patients with active severe autoimmune diseases; patients with active systemic severe infection |
| Place of origin | China |
| Prescription type | Prescription-only |
| Storage Conditions | Refrigerate at 2°C to 8°C, do not freeze, and avoid direct sunlight |
| Manufacturer | ShenZhou Cell Engineering Co., Ltd |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | S20250011 |
| Approval Date | Feb 8, 2025 |
| Shelf Life | 24 months |
How to use ?
Recommended Dose: 200mg intravenous infusion once every 3 weeks.
Time: Each infusion lasts 60 minutes, and the medication cycle is 21 days. The medication is continued until disease progression or intolerable immune toxic reactions occur.
Instructions for use: Dilute the medicinal solution with normal saline for intravenous infusion, and intravenous push injection is prohibited. Pre-medication can be given according to clinical specifications to prevent infusion reactions.
Interaction: Concomitant use of systemic glucocorticoids and immunosuppressants will reduce the anti-tumor efficacy of PD-1 inhibitors.
Side effects: Fatigue, hypothyroidism, rash, diarrhea, immune-related pneumonitis, infusion reactions, anemia and neutropenia when combined with chemotherapy.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What cancer does Finotonlimab Injection treat?
It is used for first-line treatment of recurrent and metastatic head and neck squamous cell carcinoma combined with platinum chemotherapy.
What is Finotonlimab Injection's immunotherapy mechanism?
It blocks the PD-1/PD-L1 immune checkpoint pathway to restore endogenous T-cell anti-tumor immune responses.
What severe conditions contraindicate Finotonlimab Injection?
Active severe autoimmune diseases, active systemic infections, and severe drug hypersensitivity are contraindications.
What typical immune-related side effects may appear when using Finotonlimab Injection?
Immune pneumonitis, rash, diarrhea, hypothyroidism, and infusion reactions are common adverse events.
AnYouPing® | Finotonlimab Injection | Squamous Cell Carcinoma | DengYueRX
INN: Finotonlimab Injection
Indications: Squamous cell carcinoma
Dosage Form: Injection
Strength: 100mg(4ml)/vial
